Several clinical studies have likewise reported that Pcal treatment lowered NGAL and several pro-inflammatory cytokines in chronic kidney disease patients [29], and the drug also reduced albuminuria and halted the onset and progression of nephropathy in diabetic patients [24,27,28]. Here, LCN2 is linked to chronic kidney disease.